Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C3H3O3.Na |
| Molecular Weight | 110.0439 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(=O)C([O-])=O
InChI
InChIKey=DAEPDZWVDSPTHF-UHFFFAOYSA-M
InChI=1S/C3H4O3.Na/c1-2(4)3(5)6;/h1H3,(H,5,6);/q;+1/p-1
CTI-01 (ethyl pyruvate) is an investigational anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 was developed by Critical Therapeutics as a stable prodrug of pyruvate, a potent antioxidant, and a free radical scavenger. The drug showed an anti-inflammatory and tissue protection activity in animal models of pancreatitis, ischemia-reperfusion injury, sepsis, renal injury, and endotoxemia. CTI-01 was investigated in phase 2 clinical trials on patients undergoing cardiac surgery with cardiopulmonary bypass, but despite positive results in animal models, administration of EP does not appear to confer any benefit to cardiac surgical patients undergoing cardiopulmonary bypass. Besides clinical applications, ethyl pyruvate is long used as an additive to pharmaceutical preparations and foods, including candy, beverages, and baked goods. It is generally recognized as safe by the FDA.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: WP1290 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Inactive ingredient | Rejuvesol Approved UseRejuvesol ® Solution is intended only to be used as an in vitro processing solution for the rejuvenation of a unit of RBC. Launch Date1997 |
|||
| Palliative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The cytokine activity of HMGB1--extracellular escape of the nuclear protein. | 2005 Oct |
|
| Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa. | 2006 |
|
| Bench-to-bedside review: critical illness-associated cognitive dysfunction--mechanisms, markers, and emerging therapeutics. | 2006 |
|
| Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells. | 2006 Dec |
|
| Highly enantioselective direct reductive coupling of conjugated alkynes and alpha-ketoesters via rhodium-catalyzed asymmetric hydrogenation. | 2006 Jan 25 |
|
| Introduction to serial reviews on redox signaling in immune function and cellular responses in lung injury and diseases. | 2006 Jul 1 |
|
| [Effect of ethyl pyruvate on peroxidation injury of intestinal mucosa in rats with severe abdominal infection]. | 2006 Mar |
|
| [Effect of treatment with ethyl pyruvate on multiple organ dysfunction and mortality following delayed resuscitation after burn injury in rat]. | 2006 Mar |
|
| Determination of geometric orientation of adsorbed cinchonidine on Pt and Fe and quiphos on Pt nanoclusters via DRIFTS. | 2006 Mar 21 |
|
| Pyruvate is an endogenous anti-inflammatory and anti-oxidant molecule. | 2006 May |
|
| [Relation between level of expression of high mobility group protein B1 in hepatic tissue with the severity and prognosis of sepsis in rat]. | 2006 Nov |
|
| Haemodynamic and metabolic effects of resuscitation with Ringer's ethyl pyruvate in the acute phase of porcine endotoxaemic shock. | 2006 Nov |
|
| Ethyl pyruvate attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. | 2006 Nov 15 |
|
| Is pyruvate an endogenous anti-inflammatory molecule? | 2006 Sep |
|
| Bench-to-bedside review: High-mobility group box 1 and critical illness. | 2007 |
|
| Ethyl pyruvate: a novel treatment for sepsis. | 2007 |
|
| HMGB1 as a potential therapeutic target. | 2007 |
|
| Ethyl pyruvate: a novel treatment for sepsis. | 2007 Apr |
|
| Ethyl pyruvate: a novel anti-inflammatory agent. | 2007 Apr |
|
| Ethyl pyruvate induces necrosis-to-apoptosis switch and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. | 2007 Aug |
|
| Role of guiding groups in cinchona-modified platinum for controlling the sense of enantiodifferentiation in the hydrogenation of ketones. | 2007 Aug 29 |
|
| Oxidative damage in rat erythrocyte membranes following ethanol intake: effect of ethyl pyruvate. | 2007 Aug 30 |
|
| Beneficial effects of ethyl pyruvate in septic shock from peritonitis. | 2007 Feb |
|
| Enantioselective hydrogenation of ethyl pyruvate over diop modified Pt nanoclusters. Determination of geometry of the ligand adsorption mode via DRIFTS. | 2007 Feb 21 |
|
| Promising therapeutic agents for sepsis. | 2007 Jan |
|
| Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiation. | 2007 Nov |
|
| Intrapulmonary delivery of ethyl pyruvate attenuates lipopolysaccharide- and lipoteichoic acid-induced lung inflammation in vivo. | 2007 Nov |
|
| Management of sepsis. | 2007 Nov 3 |
|
| A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. | 2007 Nov 7 |
|
| Protective effect of ethyl pyruvate on msP rat leukocytes damaged by alcohol intake. | 2007 Nov-Dec |
|
| The protective effect of ethyl pyruvate on lung injury after burn in rats. | 2007 Oct |
|
| Ethyl pyruvate improves survival and ameliorates distant organ injury in rats with severe acute pancreatitis. | 2007 Oct |
|
| Exogenous ethyl pyruvate versus pyruvate during metabolic recovery after oxidative stress in neonatal rat cerebrocortical slices. | 2007 Oct |
|
| Sulfur mustard toxicity following dermal exposure: role of oxidative stress, and antioxidant therapy. | 2007 Oct 30 |
|
| [Effect of ethyl pyruvate on renal high mobility group box-1 protein expression and acute kidney injury in rats with delayed resuscitation after thermal injury]. | 2007 Sep 1 |
|
| The first organocatalytic carbonyl-ene reaction: isomerisation-free C-C bond formations catalysed by H-bonding thio-ureas. | 2007 Sep 14 |
|
| Ethyl pyruvate. | 2008 Apr |
|
| Targeting the lipopolysaccharides: still a matter of debate? | 2008 Apr |
|
| Ethyl pyruvate reduces germ cell-specific apoptosis and oxidative stress in rat model of testicular torsion/detorsion. | 2008 Apr |
|
| Bull's eye missed by the magic bullet: preclinical investigations, publication bias, and promising new interventions. | 2008 Apr |
|
| Ethyl pyruvate decreased early nuclear factor-kappaB levels but worsened survival in lipopolysaccharide-challenged mice. | 2008 Apr |
|
| Sepsis: from bench to bedside. | 2008 Feb |
|
| Protective effects of ethyl pyruvate treatment on paraquat-intoxicated rats. | 2008 Jan |
|
| [Effect of ethyl pyruvate on indices of tissue oxygenation and perfusion in dogs with septic shock]. | 2008 Jan |
|
| The effect of ethyl pyruvate on oxidative stress in intestine and bacterial translocation after thermal injury. | 2008 Jan |
|
| [Protective effect of ethyl pyruvate on barrier function of intestinal mucosa in dogs with septic shock]. | 2008 Mar |
|
| Ethyl pyruvate inhibits hypoxic pulmonary vasoconstriction and attenuates pulmonary artery cytokine expression. | 2008 Mar |
|
| Synthesis and biological activity of functionalized indole-2-carboxylates, triazino- and pyridazino-indoles. | 2008 May |
|
| The role of high mobility group box1 in pulmonary fibrosis. | 2008 Oct |
|
| Relationship between high-mobility group box 1 protein release and T-cell suppression in rats after thermal injury. | 2008 Oct |
Sample Use Guides
In a clinical trial, 7,500 mg of ethyl pyruvate was administered intravenously starting after the induction of general anesthesia followed by 5 more doses of 7,500 mg administered every 6 hours. As an additive to pharmaceutical products and foods, ethyl pyruvate is administered orally
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
165602
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
||
|
DSLD |
3003 (Number of products:1)
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
113-24-6
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY | |||
|
DTXSID6040614
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY | |||
|
100000128100
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY | |||
|
SODIUM PYRUVATE
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY | |||
|
SUB34799
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY | |||
|
204-024-4
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY | |||
|
POD38AIF08
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY | |||
|
50144
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY | |||
|
DBSALT001546
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY | |||
|
POD38AIF08
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY | |||
|
1358847
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
23662274
Created by
admin on Fri Dec 15 15:12:28 GMT 2023 , Edited by admin on Fri Dec 15 15:12:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
